All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Krolewiecki, 2020 0.49 [0.01; 26.05]
Silva, 2021 0.46 [0.03; 8.02]
0.56 [0.31 ; 1.00 ] FACCT Trial, 2021, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Krolewiecki, 2020, Silva, 2021 6 0% 1,613 moderate not evaluable deathsdetailed results Abd-Elsalam, 2021 0.74 [0.16; 3.42]
ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.43 [0.13; 1.44]
Dabbous HM, 2020 0.51 [0.02; 15.41]
FACCT Trial, 2021 0.96 [0.44; 2.08]
GS-US-540-5773 (Goldman), 2020 0.73 [0.37; 1.44]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
HC-nCoV (Shanghai), 2020 1.00 [0.02; 53.89]
Hung et al., 2020 0.47 [0.01; 24.30]
I-TECH (Lim), 2022 0.31 [0.09; 1.09]
Khamis, 2020 0.83 [0.23; 2.96]
Kirti, 2021 0.12 [0.01; 2.36]
Krolewiecki, 2020 0.49 [0.01; 26.05]
NCT04342650, 2020 0.95 [0.02; 48.42]
NCT04523831 (Mahmud), 2020 0.16 [0.01; 3.25]
NCT04542694, 2020 1.00 [0.02; 50.90]
Ren, 2020 1.00 [0.02; 55.80]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Rocco, 2020 1.02 [0.02; 51.70]
Shenoy S, 2021 1.32 [0.58; 2.99]
Solaymani-Dodaran, 2021 1.22 [0.66; 2.26]
Udwadia, 2020 0.50 [0.02; 15.03]
Zhaowei Chen, 2020 1.00 [0.02; 52.04]
0.84 [0.64 ; 1.10 ] Abd-Elsalam, 2021, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, Dabbous HM, 2020, FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Hung et al., 2020, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Krolewiecki, 2020, NCT04342650, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Shenoy S, 2021, Solaymani-Dodaran, 2021, Udwadia, 2020, Zhaowei Chen, 2020 26 0% 5,858 moderate critical deaths (time to event analysis only)detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.64 [0.18; 2.24]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.64 [0.28 ; 1.48 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,141 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.99 [0.57; 1.72]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
ELACOI (lopinavir/ritonavir), 2020 3.69 [0.37; 36.57]
ELACOI (Standard of care), 2020 0.86 [0.06; 11.36]
I-TECH (Lim), 2022 1.25 [0.87; 1.80]
Kamran, 2020 0.95 [0.32; 2.78]
Li T, 2020 0.48 [0.01; 27.44]
NCT04523831 (Mahmud), 2020 0.44 [0.23; 0.84]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.53 [0.15; 1.95]
Rocco, 2020 1.02 [0.29; 3.58]
Zhaowei Chen, 2020 0.11 [0.01; 2.19]
0.94 [0.70 ; 1.26 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, I-TECH (Lim), 2022, Kamran, 2020, Li T, 2020, NCT04523831 (Mahmud), 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Rocco, 2020, Zhaowei Chen, 2020 11 20% 2,777 moderate low clinical improvementdetailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Chachar, 2020 1.19 [0.38; 3.72]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.81 [0.54; 1.22]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
Hung et al., 2020 3.92 [1.66; 9.24]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
NCT04542694, 2020 2.10 [1.04; 4.24]
Rocco, 2020 0.81 [0.52; 1.27]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Tang, 2020 1.01 [0.59; 1.74]
Udwadia, 2020 1.75 [1.10; 2.79]
1.24 [0.98 ; 1.57 ] AVIFAVIR, 2020, Chachar, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020 14 67% 3,634 moderate low clinical improvement (14-day)detailed results AVIFAVIR, 2020 0.53 [0.13; 2.19]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.01 [0.58; 1.76]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.82 [0.47; 1.43]
GS-US-540-5773 (Goldman), 2020 1.53 [1.02; 2.29]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
Ruzhentsova T, 2020 1.28 [1.05; 1.56]
1.24 [1.03 ; 1.48 ] AVIFAVIR, 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020 8 25% 2,632 moderate not evaluable clinical improvement (21-day)detailed results Li T, 2020 2.09 [0.04; 119.96]
2.09 [0.04 ; 119.96 ] Li T, 2020 1 0% 18 NA not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
Ruzhentsova T, 2020 1.11 [0.96; 1.29]
Udwadia, 2020 1.75 [1.10; 2.79]
1.47 [1.06 ; 2.04 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Ruzhentsova T, 2020, Udwadia, 2020 4 59% 1,102 moderate not evaluable clinical improvement (7-day)detailed results Chachar, 2020 1.19 [0.38; 3.72]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 0.89 [0.59; 1.35]
GS-US-540-5773 (Goldman), 2020 1.46 [0.95; 2.23]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
Kirti, 2021 0.90 [0.77; 1.06]
NCT04523831 (Mahmud), 2020 1.93 [1.27; 2.93]
NCT04542694, 2020 2.10 [1.04; 4.24]
Rocco, 2020 0.81 [0.52; 1.27]
Ruzhentsova T, 2020 1.50 [1.02; 2.21]
1.21 [0.98 ; 1.50 ] Chachar, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Kirti, 2021, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Rocco, 2020, Ruzhentsova T, 2020 10 63% 2,797 moderate critical clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
GS-US-540-5773 (Goldman), 2020 0.79 [0.61; 1.02]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
Hung et al., 2020 3.92 [1.66; 9.24]
NCT04523831 (Mahmud), 2020 1.89 [1.06; 3.38]
Ruzhentsova T, 2020 1.63 [1.14; 2.34]
Shenoy S, 2021 0.99 [0.77; 1.28]
Shinkai, 2021 1.40 [0.91; 2.15]
Solaymani-Dodaran, 2021 0.94 [0.75; 1.17]
Tang, 2020 1.01 [0.59; 1.74]
Udwadia, 2020 1.75 [1.10; 2.79]
1.17 [0.99 ; 1.39 ] FACCT Trial, 2021, GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, NCT04523831 (Mahmud), 2020, Ruzhentsova T, 2020, Shenoy S, 2021, Shinkai, 2021, Solaymani-Dodaran, 2021, Tang, 2020, Udwadia, 2020 12 67% 3,727 moderate critical hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
Kirti, 2021 1.20 [0.73; 1.98]
Li T, 2020 10.00 [1.03; 97.50]
RIVET-COV (Mohan) (12mg and 24mg), 2021 2.31 [0.66; 8.04]
Shenoy S, 2021 1.06 [0.85; 1.32]
Udwadia, 2020 1.41 [0.97; 2.03]
1.16 [0.91 ; 1.48 ] FACCT Trial, 2021, Kirti, 2021, Li T, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Shenoy S, 2021, Udwadia, 2020 6 43% 1,439 moderate serious hospitalizationdetailed results Holubar M, 2021 0.12 [0.01; 2.26]
0.12 [0.01 ; 2.26 ] Holubar M, 2021 1 0% 149 NA not evaluable mechanical ventilationdetailed results Abd-Elsalam, 2021 1.00 [0.20; 5.11]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.77 [0.81; 3.87]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.54 [0.70; 3.37]
GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
I-TECH (Lim), 2022 0.41 [0.13; 1.30]
Kirti, 2021 0.20 [0.00; 8.69]
Li T, 2020 0.40 [0.04; 3.90]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Solaymani-Dodaran, 2021 1.62 [0.85; 3.08]
Udwadia, 2020 0.06 [0.01; 0.83]
0.84 [0.48 ; 1.47 ] Abd-Elsalam, 2021, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, I-TECH (Lim), 2022, Kirti, 2021, Li T, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Solaymani-Dodaran, 2021, Udwadia, 2020 11 39% 2,783 moderate critical mechanical ventilation (time to event analysis only)detailed results Udwadia, 2020 0.06 [0.01; 0.83]
0.06 [0.01 ; 0.83 ] Udwadia, 2020 1 0% 14 NA not evaluable radiologic improvement (14-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.48 [0.02; 11.28]
ELACOI (Standard of care), 2020 0.18 [0.01; 3.99]
Rashad A (AZI vs SoC), 2021 1.64 [0.94; 2.88]
1.17 [0.42 ; 3.26 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Rashad A (AZI vs SoC), 2021 3 16% 252 moderate not evaluable radiologic improvement (7-day)detailed results ELACOI (lopinavir/ritonavir), 2020 0.10 [0.00; 2.09]
ELACOI (Standard of care), 2020 0.08 [0.00; 1.71]
Ren, 2020 19.00 [0.85; 422.73]
Zhaowei Chen, 2020 3.43 [1.10; 10.70]
0.98 [0.09 ; 10.24 ] ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Ren, 2020, Zhaowei Chen, 2020 4 72% 128 moderate not evaluable viral clearance detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
HC-nCoV (Shanghai), 2020 0.46 [0.04; 5.75]
Holubar M, 2021 0.76 [0.48; 1.20]
Hung et al., 2020 4.37 [1.86; 10.25]
NCT04542694, 2020 13.03 [2.96; 57.24]
Ren, 2020 28.50 [1.27; 640.66]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang, 2020 0.85 [0.58; 1.23]
Udwadia, 2020 1.37 [0.94; 1.98]
1.39 [1.03 ; 1.87 ] AVIFAVIR, 2020, Chaccour, 2020, Dabbous HM, 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Hung et al., 2020, NCT04542694, 2020, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020 14 69% 1,342 moderate critical viral clearance (time to event analysis only)detailed results Ahmed, 2020 4.10 [1.12; 14.99]
Holubar M, 2021 0.76 [0.48; 1.20]
Hung et al., 2020 4.37 [1.86; 10.25]
Ruzhentsova T, 2020 1.28 [0.92; 1.79]
Tang, 2020 0.85 [0.58; 1.23]
Udwadia, 2020 1.37 [0.94; 1.98]
1.35 [0.91 ; 2.02 ] Ahmed, 2020, Holubar M, 2021, Hung et al., 2020, Ruzhentsova T, 2020, Tang, 2020, Udwadia, 2020 6 75% 816 moderate not evaluable viral clearance by day 14detailed results Ahmed, 2020 4.10 [1.12; 14.99]
AVIFAVIR, 2020 3.08 [0.62; 15.39]
Bukhari, 2021 0.91 [0.02; 46.94]
ELACOI (lopinavir/ritonavir), 2020 1.28 [0.19; 8.76]
ELACOI (Lopinavir/ritonavir), 2020 1.84 [0.40; 8.38]
ELACOI (Standard of care), 2020 2.80 [0.31; 25.53]
Li T, 2020 1.00 [0.03; 34.67]
Ruzhentsova T, 2020 0.99 [0.93; 1.06]
1.32 [0.87 ; 2.01 ] Ahmed, 2020, AVIFAVIR, 2020, Bukhari, 2021, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Li T, 2020, Ruzhentsova T, 2020 8 13% 524 moderate serious viral clearance by day 7detailed results AVIFAVIR, 2020 3.89 [1.23; 12.29]
Bukhari, 2021 11.56 [3.53; 37.91]
Chaccour, 2020 0.92 [0.77; 1.09]
Dabbous HM, 2020 1.33 [0.60; 2.93]
ELACOI (Lopinavir/ritonavir), 2020 1.08 [0.41; 2.89]
ELACOI (lopinavir/ritonavir), 2020 0.30 [0.05; 1.91]
ELACOI (Standard of care), 2020 0.67 [0.10; 4.58]
Kirti, 2021 0.80 [0.43; 1.50]
Ren, 2020 28.50 [1.27; 640.66]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.10 [0.50; 2.39]
Ruzhentsova T, 2020 1.05 [0.92; 1.20]
1.22 [0.90 ; 1.65 ] AVIFAVIR, 2020, Bukhari, 2021, Chaccour, 2020, Dabbous HM, 2020, ELACOI (Lopinavir/ritonavir), 2020, ELACOI (lopinavir/ritonavir), 2020, ELACOI (Standard of care), 2020, Kirti, 2021, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020 11 67% 803 moderate low ICU admissiondetailed results FACCT Trial, 2021 1.42 [0.79; 2.55]
I-TECH (Lim), 2022 0.78 [0.27; 2.23]
Khamis, 2020 1.03 [0.35; 3.03]
Kirti, 2021 0.90 [0.30; 2.70]
Rocco, 2020 4.11 [0.18; 91.83]
Solaymani-Dodaran, 2021 1.23 [0.70; 2.18]
1.19 [0.85 ; 1.67 ] FACCT Trial, 2021, I-TECH (Lim), 2022, Khamis, 2020, Kirti, 2021, Rocco, 2020, Solaymani-Dodaran, 2021 6 0% 1,710 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 0.81 [0.64; 1.03]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.03 [0.83 ; 1.28 ] GS-US-540-5773 (Goldman), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 66% 1,193 moderate not evaluable severe COVID-19 occurrencedetailed results ELACOI (Lopinavir/ritonavir), 2020 0.30 [0.07; 1.27]
0.30 [0.07 ; 1.27 ] ELACOI (Lopinavir/ritonavir), 2020 1 0% 69 NA not evaluable serious adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.87 [0.36; 9.75]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.02 [0.20; 5.10]
GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
Hung et al., 2020 0.23 [0.01; 7.12]
Krolewiecki, 2020 1.00 [0.03; 31.59]
NCT04523831 (Mahmud), 2020 3.97 [0.18; 88.58]
NCT04542694, 2020 6.15 [0.30; 124.49]
Ren, 2020 1.00 [0.02; 55.80]
RIVET-COV (Mohan) (12mg and 24mg), 2021 0.52 [0.01; 26.47]
Ruzhentsova T, 2020 2.06 [0.09; 46.40]
Shinkai, 2021 2.80 [0.14; 56.95]
Udwadia, 2020 1.03 [0.02; 52.48]
0.75 [0.47 ; 1.19 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Hung et al., 2020, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 13 0% 3,012 moderate critical acute kidney injury detailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1.18 [0.44; 3.18]
1.18 [0.44 ; 3.18 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable adverse eventsdetailed results Chaccour, 2020 1.00 [0.20; 5.07]
ChiCTR2000030054-HCQ (Chen), 2020 5.00 [0.85; 29.57]
Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.22 [1.43; 3.44]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.21 [0.82; 1.78]
GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
HC-nCoV (Shanghai), 2020 1.45 [0.26; 8.01]
Holubar M, 2021 2.07 [0.89; 4.83]
Krolewiecki, 2020 1.53 [0.42; 5.58]
NCT04523831 (Mahmud), 2020 18.57 [1.07; 322.77]
NCT04542694, 2020 1.00 [0.54; 1.85]
Ren, 2020 0.12 [0.01; 2.86]
RIVET-COV (Mohan) (12mg and 24mg), 2021 1.25 [0.45; 3.47]
Ruzhentsova T, 2020 1.90 [0.96; 3.80]
Shinkai, 2021 19.54 [7.77; 49.11]
Udwadia, 2020 6.36 [2.43; 16.65]
1.92 [1.34 ; 2.74 ] Chaccour, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, HC-nCoV (Shanghai), 2020, Holubar M, 2021, Krolewiecki, 2020, NCT04523831 (Mahmud), 2020, NCT04542694, 2020, Ren, 2020, RIVET-COV (Mohan) (12mg and 24mg), 2021, Ruzhentsova T, 2020, Shinkai, 2021, Udwadia, 2020 17 70% 3,447 moderate low arrhythmiadetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 2.24 [0.23; 21.69]
2.24 [0.23 ; 21.69 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable elevated liver enzymesdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 3.48 [1.40; 8.64]
3.48 [1.40 ; 8.64 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 416 NA not evaluable long QTdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 9.79 [1.27; 75.50]
9.79 [1.27 ; 75.50 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 174 NA not evaluable renal impairmentdetailed results COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1.35 [0.47; 3.86]
1.35 [0.47 ; 3.86 ] COALITION I Covid-19 Brazil (AZI, Cavalcanti), 2020 1 0% 331 NA not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 0.50 [0.32; 0.79]
0.50 [0.32 ; 0.79 ] GS-US-540-5773 (Goldman), 2020 1 0% 397 NA not evaluable Thromboembolic eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 0.89 [0.31; 2.55]
0.89 [0.31 ; 2.55 ] Coalition Covid-19 Brazil I (Cavalcanti) - HCQ AZI, 2020 1 0% 345 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-27 14:22 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290